%A LIU Zhi-Bao, ZHANG Jing-Hua %T Research progress of ERCC1 in non-small cell lung cancer based on the platinum drugs %0 Journal Article %D 2014 %J Journal of International Oncology %R 10.3760/cma.j.issn.1673-422X.2014.12.010 %P 909-912 %V 41 %N 12 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_9595.shtml} %8 2014-12-24 %X Excision repair cross complementing group 1 (ERCC1) gene is an enzyme of the speed limit of DNA repair protein in nucleotide excision repair (NER) pathways.Researches suggest that ERCC1 has been associated with cisplatin resistance in nonsmall cell lung cancer (NSCLC) patients. Thus, ERCC1 gene is a new target in malignant tumor gene therapy research,providing a new approach for the treatment of malignant,especially NSCLC.